Symptomatic Relief in Essential Tremor with Home Use of Non-Invasive Neuromodulation Therapy
This webinar will review the mechanisms of action for Cala Trio therapy and the results of the largest clinical trial for patients with essential tremor. The PROspective study for SymPtomatic relief of Essential tremor with Cala Therapy (PROSPECT) was a multi-center 3-month study that evaluated the effectiveness of extended home use of Cala Health’s initial product, in symptomatic relief of essential tremor (ET) in the hands.
Join the webinar to learn more about the first-ever non-invasive, targeted nerve stimulator for the treatment of ET.
Manish Gupta, MS, MBA is the Vice President of Clinical Affairs at Cala Health. Manish has over 15 years of experience in developing and executing clinical trials to gain product approvals and market acceptance in global cardiac and neurological device markets. He has held clinical affairs and medical affairs strategic leadership roles at Medtronic, Covidien, and St. Jude Medical (Abbott Labs). Under Manish’s leadership, clinical evidence generation also led to changes in AHA & ESOC guidelines. Most recently at Cala, he oversaw the design and execution of the PROSPECT Study (the largest Essential Tremor study conducted to date) across 26 US centers.
Cala Trio Introductory Webinar for Physicians
This webinar presents the clinical evidence for Cala Trio and explains the user experience of this novel technology, first-in-class therapy. Get all your questions answered about this breakthrough therapy for essential tremor. Learn from the Cala Health experts including Cala Trio Product Manager, Tony Francisco. Dr. Khosla shares her experience in treating over 50 patients with the Cala Trio therapy. Listen now to learn about bringing individualized therapy that effectively relieves hand tremors into your practice this year.